Evaluation of Human Papillomavirus Vaccine Coverage in Girls and Young Women With Chronic Disease (MC-HPV)

Assistance Publique - Hôpitaux de Paris

Status: Completed

Conditions: Chronic Condition; Human Papillomavirus Vaccine

Treatments: Other: Questionnaire

Study type: Observational

Funder types: Other

Identifiers

NCT06158802

2021-A02421-40 (Other Identifier)

APHP210417

Details and patient eligibility

About

The main objective of the study is to determine the vaccination coverage rate for human papillomavirus in adolescents aged 11 to 20 with chronic disease and treated at the Necker-Enfants Malades Hospital, compared to a population witnessed adolescent girls aged 11 to 20 years without chronic disease.

Full description

Girls and young women with chronic condition are at higher risk for infections that can be prevented by vaccination. Human papillomavirus infection is very common, one of the three most common in the general population. A vaccine exists to significantly prevent this infection and its complications.

In France, it is advisable to vaccinate girls and boys from the age of 9 years and as soon as possible in the case of acquired immunodeficiency since these patients are more likely to be suffering from cancer induced by the human papillomavirus.

In France, the overall rate of vaccination coverage for girls is 21%, which is significantly lower than in several other industrialized countries.

The vaccination coverage rate for human papillomavirus in patients with chronic diseases may be even lower.

The main objective of the study is to determine the vaccination coverage rate for human papillomavirus in adolescents aged 11 to 20 with chronic condition and treated at the Necker-Enfants Malades Hospital, compared to a population witnessed adolescent girls aged 11 to 20 years without chronic disease.

Enrollment: 223 patients

Sex: Female

Ages: 11 to 20 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Information and non-opposition of major patients and holders of parental authority of minor patients and minor patients

• Girls and young women aged 11 to 20

• To be followed at the Necker-Enfants Malades Hospital ("chronic condition" group)

• To be followed at the Specialized Medical Center for Children and Adolescents ("control" group)

• Have a chronic condition ("chronic condition" group) :

  • Diabetes type 1
  • Metabolic diseases
  • Patients followed in immuno-hematology
  • Cystic Fibrosis
  • Sickle
  • Kidney transplant
  • Heart Disease
  • Inflammatory bowel diseases
  • Rare anorectal and pelvic anomalies

• Live in France

• Comprehension of the French language (oral and written)

Exclusion criteria

• Have a contraindication to the HPV vaccine - Gardasil 9 (Vidal Hoptimal, 2018)
• Have a contraindication to the HPV vaccine - Gardasil (Vidal Hopitmal, 2018)
• Have a contraindication to HPV vaccine - Cervarix (Vidal Hoptimal, 2018)

Trial design

223 participants in 2 patient groups

Chronic condition

Description:

Girls and young women between the ages of 11 and 20 suffering from chronic condition

Treatment:

Other: Questionnaire

Control

Description:

Girls and young women between the ages of 11 and 20 in good health

Treatment:

Other: Questionnaire